STAMPEDE Trial: Comprehensive Overview
Trial Design and Structure
STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) is a groundbreaking multi-arm, multi-stage (MAMS) platform trial that revolutionized prostate cancer treatment by demonstrating that adding abiraterone acetate plus prednisolone to androgen deprivation therapy (ADT) significantly improves survival across multiple disease states. 1, 2, 3
Core Design Features
- Platform structure: The trial uses an innovative adaptive design allowing multiple treatment arms to be tested simultaneously against a shared control group, with the ability to stop ineffective arms and add new ones mid-trial 4
- Patient population: Men with locally advanced or metastatic prostate cancer starting long-term hormone therapy, with no age restrictions and WHO performance status 0-2 5, 3
- Heterogeneous cohorts: Unlike LATITUDE which enrolled only high-risk metastatic patients, STAMPEDE included three distinct populations: metastatic disease (M1, n=941), node-positive disease (N1, n=369), and high-risk node-negative disease (N0 M0, n=509) 1, 2
Abiraterone Arm: Primary Results
Metastatic Disease Outcomes
In the metastatic cohort, abiraterone plus prednisolone added to ADT reduced the risk of death by 38% compared to ADT alone, with median overall survival of 76.6 months versus 45.7 months (HR 0.62; 95% CI 0.53-0.73; P<0.001). 6, 3
- Radiographic progression-free survival: Dramatically improved with HR 0.31 (P<0.0001) in M1 patients 1
- PSA progression: Delayed from median 7.4 months to 33.2 months 1
- Long-term durability: Survival benefits maintained beyond 7 years of follow-up (median 96 months) 6
Non-Metastatic Disease Outcomes
For high-risk non-metastatic disease, abiraterone demonstrated a 40% reduction in mortality risk (HR 0.60; 95% CI 0.48-0.73; P<0.0001) and a remarkable 79% improvement in failure-free survival (HR 0.21; 95% CI 0.15-0.31). 7, 5
- Metastasis-free survival: 82% at 6 years with combination therapy versus 69% with ADT alone (HR 0.53; 95% CI 0.44-0.64; P<0.0001) 5
- Treatment protocol: Abiraterone 1000 mg daily plus prednisolone 5 mg daily for 2 years when combined with radiotherapy; continued until progression if radiotherapy omitted 1, 5
- Radiotherapy mandate: Required for node-negative disease and strongly encouraged for node-positive disease, delivered at 6-9 months post-randomization 7, 5
Critical Age-Related Findings
A crucial and often overlooked finding is the substantial heterogeneity by age: men under 70 years experienced dramatically greater survival benefit (HR 0.51) compared to men 70 years or older (HR 0.94), with older patients experiencing significantly higher toxicities. 1, 8, 7
- Toxicity differential: Grade 3-5 adverse events occurred in 47% of older patients versus 33% in younger patients 1, 8
- Treatment-related deaths: Nine deaths in the abiraterone group versus three in the control group, predominantly in older patients 1, 3
- Clinical implication: This age heterogeneity should strongly influence treatment decisions, particularly in men ≥70 years with significant comorbidities 8, 7
Safety Profile and Monitoring Requirements
Common Adverse Events
Grade 3 or higher adverse events occurred in 37-47% of patients receiving abiraterone plus prednisolone alone, and 58% when combined with enzalutamide, compared to 29-33% with ADT alone. 5, 6
- Mineralocorticoid excess effects: Hypertension (5-14% grade 3+), hypokalemia, and edema are the most common serious adverse events 1, 5
- Hepatotoxicity: Grade 3-5 liver toxicity occurs in approximately 7% of patients, with alanine transaminitis being the most frequent manifestation 8, 5
- Cardiac events: Severe hypertension or cardiac disorders occur in approximately 10% of patients, with cardiac causes being the most common cause of treatment-related death 8, 5, 6
- Overall discontinuation rate: Approximately 12% due to adverse events 1, 8
Mandatory Monitoring Protocol
Baseline assessment must include blood pressure, serum potassium, comprehensive liver function tests, and cardiac evaluation, with ongoing monitoring throughout treatment. 8, 7
- Regular surveillance: Monitor for mineralocorticoid excess (hypertension, hypokalemia), hepatotoxicity, and cardiac disorders at each visit 8
- Dose modifications: Required for grade 3+ hepatotoxicity or uncontrolled hypertension despite medical management 1
Abiraterone Plus Enzalutamide Combination: Negative Results
The STAMPEDE trial definitively demonstrated that combining enzalutamide with abiraterone and ADT does NOT improve survival compared to abiraterone and ADT alone (interaction HR 1.05; 95% CI 0.83-1.32; P=0.71), while substantially increasing toxicity. 5, 6
- Survival outcomes: Median overall survival was 73.1 months with triple therapy versus 76.6 months with abiraterone alone, showing no benefit 6
- Toxicity burden: Grade 3-5 adverse events increased to 68% with triple therapy versus 54% with abiraterone alone 5, 6
- Clinical recommendation: Enzalutamide and abiraterone should NOT be combined for patients starting long-term ADT 6
Guideline Integration and Clinical Recommendations
NCCN Guidelines
The NCCN designates abiraterone acetate 1000 mg daily plus prednisone 5 mg daily as a Category 1 recommendation (highest level of evidence and consensus) for both metastatic castration-naïve and high-risk non-metastatic prostate cancer. 1, 8
ASCO Guidelines
ASCO strongly recommends (evidence quality: high; strength: strong) abiraterone 1000 mg with prednisone 5 mg daily for men with newly diagnosed metastatic prostate cancer, particularly those meeting high-risk criteria. 2
- High-risk definition: At least two of the following: Gleason score ≥8, ≥3 bone lesions, or visceral metastases (per LATITUDE criteria) 2
- Treatment duration: Until progression for metastatic disease; 2 years for non-metastatic disease receiving radiotherapy 1, 2
ESMO Guidelines
ESMO recommends abiraterone as a Level I, Grade A evidence option for metastatic hormone-naïve prostate cancer, with particular emphasis on high-volume disease. 9
Key Distinctions from LATITUDE Trial
While LATITUDE and STAMPEDE are mutually supportive for high-risk metastatic disease, STAMPEDE uniquely provides evidence for lower-risk and non-metastatic populations that LATITUDE did not address. 2
- LATITUDE eligibility: Only de novo metastatic disease with high-risk features (≥2 of: Gleason ≥8, ≥3 bone metastases, visceral disease) 1, 10
- STAMPEDE eligibility: Included high-risk N0 M0, N1 M0, and M1 disease, with 95% newly diagnosed and 5% relapsing disease 1, 3
- Crossover rates: LATITUDE had only 27% crossover to life-prolonging therapy versus 58% in STAMPEDE, potentially affecting survival estimates 1
Quality of Life Outcomes
Patient-reported outcomes were significantly improved with abiraterone, including reductions in pain intensity progression, fatigue, functional decline, and prostate cancer-related symptoms, with overall enhancement of health-related quality of life. 1, 7
Clinical Decision Algorithm
For Metastatic Disease (M1)
Age <70 years with good performance status: Strongly recommend abiraterone 1000 mg daily plus prednisone 5 mg daily added to ADT, continued until progression (HR 0.61 for survival) 1, 6, 3
Age ≥70 years: Carefully weigh the reduced survival benefit (HR 0.94) against substantially increased toxicity risk; consider patient comorbidities, baseline cardiac function, and liver function before proceeding 1, 8
For High-Risk Non-Metastatic Disease (N0 or N1)
Node-negative with ≥2 high-risk factors (T3/4, PSA >40, Gleason 8-10): Recommend abiraterone 1000 mg daily plus prednisone 5 mg daily for 2 years, combined with ADT for 3 years and mandatory radiotherapy (HR 0.60 for survival) 7, 5
Node-positive disease: Same regimen with radiotherapy strongly encouraged; treatment duration 2 years with radiotherapy or until progression without radiotherapy 7, 5